BioLineRx (NASDAQ:BLRX) Releases Quarterly Earnings Results, Misses Expectations By $0.62 EPS

BioLineRx (NASDAQ:BLRX) announced its earnings results on Monday. The biotechnology company reported ($0.77) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.62), Zacks reports. The firm had revenue of $0.29 million during the quarter, compared to analysts’ expectations of $0.50 million. BioLineRx had a negative net margin of 563.70% and a negative return on equity of 37.73%.

BioLineRx Stock Performance

Shares of NASDAQ:BLRX opened at $2.60 on Monday. The company has a debt-to-equity ratio of 0.16, a quick ratio of 1.43 and a current ratio of 1.58. The stock has a market capitalization of $11.36 million, a price-to-earnings ratio of -1.35 and a beta of 1.54. BioLineRx has a 1-year low of $2.15 and a 1-year high of $4.56. The company has a 50 day moving average price of $2.92 and a 200 day moving average price of $2.84.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of BioLineRx in a report on Friday, July 17th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, BioLineRx currently has an average rating of “Sell”.

BioLineRx Company Profile

BioLineRx (NASDAQ: BLRX) is a clinical-stage biopharmaceutical company that discovers and develops novel small-molecule therapies to address unmet medical needs. The company focuses on identifying promising drug candidates through licensing and collaboration agreements with academic institutions and biotech innovators, then advancing these candidates through preclinical and clinical development stages. BioLineRx’s pipeline spans oncology, immunology and inflammatory diseases, central nervous system disorders and pain management.

Among its clinical programs, BioLineRx is advancing targeted cancer therapies designed to improve outcomes for patients with difficult-to-treat tumors.